KCNJ11 and congenital isolated hyperinsulinism: Homozygous and compound heterozygous mutations, as well as dominantly inherited mutations in ABCC8/KCNJ11 cause diffuse CHI, which is often unresponsive to first line diazoxide treatment and therefore suitable for therapy with second line somatostatin receptor ligands (SRLs).